World's Best Scientists 2026 revealed!
Mark C. Poznansky

Mark C. Poznansky

D-Index & Metrics

Immunology

D-Index
49
Citations
13116
World Ranking
4304
National Ranking
1956

Mark C. Poznansky publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Mark C. Poznansky sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 177 publications — 26th percentile

26% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Mark C. Poznansky D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Mark C. Poznansky sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 49 D-Index — 13th percentile

13% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Mark C. Poznansky is affiliated with Harvard University in the United States. Their research spans multiple fields within medicine and biochemistry, genetics, and molecular biology.

Their work focuses heavily on infectious diseases and immunology, with significant contributions in molecular biology, oncology, and genetics. Key topics in their research include SARS-CoV-2 and COVID-19 studies, clinical research on COVID-19, vector-borne infectious diseases, viral infections and vectors, viral gastroenteritis research and epidemiology, cancer genomics and diagnostics, and pancreatic function and diabetes.

Frequent co-authors collaborating with Mark C. Poznansky include:

  • Ann E. Sluder
  • Patrick M. Reeves
  • A. John Iafrate
  • Vivek Naranbhai
  • Alejandro B. Balazs

Key venues for publication feature prominently in their academic career and include:

  • The FASEB Journal
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Frontiers in Immunology
  • Cell
  • The Journal of Infectious Diseases

Representative recent papers authored or co-authored by Poznansky are:

  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, 2021, Cell
  • mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant, 2022, Cell
  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, 2021, Cell
  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity, 2021, bioRxiv (Cold Spring Harbor Laboratory)
  • Rethinking the role of hydroxychloroquine in the treatment of COVID-19, 2020, The FASEB Journal

The scholar's extensive publication record includes over 100 publications in medicine, with significant contributions to infectious diseases research, highlighting a focus on COVID-19 and related viral infections.

Best Publications

  • mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

    Unknown

  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

    Wilfredo F. Garcia-Beltran;Wilfredo F. Garcia-Beltran;Evan C. Lam;Kerri St. Denis;Adam D. Nitido

  • Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy

    Yuhui Huang;Jianping Yuan;Elda Righi;Walid S. Kamoun

  • Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor

    Gregor B. Adams;Karissa T. Chabner;Ian R. Alley;Douglas P. Olson

  • Active movement of T cells away from a chemokine.

    Mark C. Poznansky;Ivona T. Olszak;Russell Foxall;Richard H. Evans

  • CXCL12/CXCR4 Blockade Induces Multimodal Antitumor Effects That Prolong Survival in an Immunocompetent Mouse Model of Ovarian Cancer

    Elda Righi;Satoshi Kashiwagi;Jianping Yuan;Michael Santosuosso

  • Erratum: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity (Cell (2021) 184(9) (2372–2383.e9), (S0092867421002981), (10.1016/j.cell.2021.03.013))

    Wilfredo F. Garcia-Beltran;Wilfredo F. Garcia-Beltran;Evan C. Lam;Kerri St. Denis;Adam D. Nitido

  • Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector

    M Poznansky;A Lever;L Bergeron;W Haseltine

  • Replication of human immunodeficiency virus type 1 in primary dendritic cell cultures.

    E. Langhoff;E. F. Terwilliger;H. J. Bos;K. H. Kalland

  • Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines

    Unknown

  • Extracellular calcium elicits a chemokinetic response from monocytes in vitro and in vivo

    Ivona T. Olszak;Mark C. Poznansky;Richard H. Evans;Douglas Olson

  • Vectors containing hiv packaging sequences, packaging defective hiv vectors, and uses thereof

    Joseph G. Sodroski;William A. Haseltine;Mark Poznansky;Andrew Lever

  • Efficient generation of human T cells from a tissue-engineered thymic organoid

    Mark C. Poznansky;Richard H. Evans;Russell B. Foxall;Ivona T. Olszak

  • Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.

    Yang Zeng;Binghao Li;Yingying Liang;Patrick M. Reeves

  • Rethinking the role of hydroxychloroquine in the treatment of COVID-19.

    Eric A. Meyerowitz;Augustin G. L. Vannier;Morgan G. N. Friesen;Sara Schoenfeld

  • Neutrophil chemorepulsion in defined interleukin‐8 gradients in vitro and in vivo

    William G. Tharp;R. Yadav;D. Irimia;A. Upadhyaya

  • Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital.

    Tyler E. Miller;Wilfredo F. Garcia Beltran;Adam Z. Bard;Tasos Gogakos

  • Thymocyte emigration is mediated by active movement away from stroma-derived factors

    Mark C. Poznansky;Ivona T. Olszak;Richard H. Evans;Zhengyu Wang

  • Murine B16 Melanomas Expressing High Levels of the Chemokine Stromal-Derived Factor-1/CXCL12 Induce Tumor-Specific T Cell Chemorepulsion and Escape from Immune Control

    Fabrizio Vianello;Natalia Papeta;Tao Chen;Paul Kraft

  • Alginate-microencapsulation of human stem cell-derived β cells with CXCL12 prolongs their survival and function in immunocompetent mice without systemic immunosuppression.

    David A Alagpulinsa;Jenny J L Cao;Jenny J L Cao;Riley K Driscoll;Riley K Driscoll;Ruxandra F Sîrbulescu

  • Characterization and functional studies of rheumatoid synovial mast cells. Activation by secretagogues, anti-IgE, and a histamine-releasing lymphokine.

    Barry Gruber;Mark Poznansky;Eleonore Boss;Jacqueline Partin

  • Resistance to Methylprednisolone in Cultures of Blood Mononuclear Cells from Glucocorticoid-Resistant Asthmatic Patients

    M. C. Poznansky;A. C. H. Gordon;J. G. Douglas;A. S. Krajewski

  • Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.

    Wilfredo F Garcia-Beltran;Wilfredo F Garcia-Beltran;Evan C Lam;Kerri St Denis;Adam D Nitido

Frequent Co-Authors

Jeffrey A. Gelfand
Jeffrey A. Gelfand Harvard University
Elda Righi
Elda Righi University of Verona
David T. Scadden
David T. Scadden Harvard University
James F. Markmann
James F. Markmann Harvard University
Aaron G. Schmidt
Aaron G. Schmidt Ragon Institute of MGH, MIT and Harvard
Richard Coker
Richard Coker London School of Hygiene & Tropical Medicine
John T. Potts
John T. Potts Harvard University
A. John Iafrate
A. John Iafrate Harvard University
Vivek Naranbhai
Vivek Naranbhai Monash University
Joseph Sodroski
Joseph Sodroski Harvard Medical School

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, expanding your expertise through related healthcare degrees can open diverse career opportunities. Nursing programs, particularly accelerated options, offer a practical route to apply immunological knowledge in clinical settings. Programs like the 12-month accelerated nursing programs online for non nurses allow students without prior nursing backgrounds to transition quickly into the profession, combining foundational sciences with patient care.

If you are seeking more accessible entry points, consider the absn programs with high acceptance rates. These programs provide a streamlined path to a Bachelor of Science in Nursing, often designed for career changers or recent graduates of other fields.

For those focused on practical nursing roles, the best easiest lpn programs to get into offer opportunities to enter the workforce quickly while gaining essential skills that complement immunology research and healthcare delivery.

Advanced practice is another area to consider. The easiest nurse practitioner degree programs provide avenues for nurses aiming to specialize further in immunology-related conditions and patient management in diverse healthcare environments.

Best Scientists Citing Mark C. Poznansky

Trending Scientists

Recently Published Articles